Focused On-demand Library for Actin nucleation-promoting factor WAS

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.


Our library distinguishes itself through several key aspects:


  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.

  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.

  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.

  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
P42768

UPID:
WASP_HUMAN

ALTERNATIVE NAMES:
Wiskott-Aldrich syndrome protein

ALTERNATIVE UPACC:
P42768; Q9BU11; Q9UNJ9

BACKGROUND:
Actin nucleation-promoting factor WAS, known for regulating actin polymerization, is essential for efficient actin assembly, impacting cell motility and signaling. It also facilitates DNA repair and gene transcription through nuclear actin polymerization.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of Actin nucleation-promoting factor WAS could open doors to potential therapeutic strategies. Its critical function in cell structure and response to DNA damage makes it a promising target for addressing genetic disorders and enhancing cellular repair mechanisms.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.